Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Total Debt (2020 - 2026)

Treace Medical Concepts filings provide 6 years of Total Debt readings, the most recent being $57.3 million for Q4 2025.

  • On a quarterly basis, Total Debt rose 7.55% to $57.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $57.3 million, a 7.55% increase, with the full-year FY2025 number at $57.3 million, up 7.55% from a year prior.
  • Total Debt hit $57.3 million in Q4 2025 for Treace Medical Concepts, up from $55.3 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $57.3 million in Q4 2025 to a low of $29.2 million in Q1 2021.
  • Median Total Debt over the past 5 years was $52.9 million (2023), compared with a mean of $47.5 million.
  • Biggest five-year swings in Total Debt: dropped 5.2% in 2021 and later skyrocketed 79.53% in 2022.
  • Treace Medical Concepts' Total Debt stood at $29.4 million in 2021, then surged by 79.5% to $52.7 million in 2022, then increased by 0.56% to $53.0 million in 2023, then increased by 0.56% to $53.3 million in 2024, then rose by 7.55% to $57.3 million in 2025.
  • The last three reported values for Total Debt were $57.3 million (Q4 2025), $55.3 million (Q3 2025), and $54.6 million (Q2 2025) per Business Quant data.